anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Previous research in lifestyle behavior weight loss intervention has 3 limitations. (1) Low-income overweight or obese mothers of young children have been significantly underrepresented. (2) Prior lifestyle interventions in overweight or obese mothers have suffered from threats to internal validity and have not specifically addressed motivation, emotion, and cognition (especially executive function), all of which are critical for promoting and maintaining healthy lifestyle behaviors and health outcomes. (3) There has been little evidence that any of the potentially efficacious strategies researched previously were even possible under real-world conditions. The proposed small pilot study builds on strength and effectively addresses limitations of prior research. The ultimate goal of the proposed study is to create a more feasible and scalable intervention that can be easily implemented and sustained in real-world settings. This self-directed, web-based goal-oriented episodic future thinking intervention will focus on increasing motivation (autonomous motivation and self-efficacy) and improving emotion (emotion control and stress) and cognition (impulsivity). the will lead to weight loss and decrease risk of chronic conditions associated with obesity, for example, hypertension, type 2 diabetes, and cancer. All eligible women will be assigned to the intervention group. The intervention will last 3 weeks and will be delivered via weekly web and individual health coaching sessions. We will enroll 30 low-income overweight or obese mothers of young children with diverse racial and ethnic backgrounds. All participants will be assessed at baseline (T1) and immediately after the three-week intervention (T2). Specific aims are to to (1) assess intervention fidelity (dose, delivery, receipt) and acceptability by the study participants, (2) investigate potential intervention impact on the primary (body weight) and secondary outcomes (waist circumference), (3) explore potential intervention impact on lifestyle behaviors (diet and physical activity), (4) explore potential intervention impact on motivation (autonomous motivation, self-efficacy, social support), emotion (emotion control, stress), and cognition (impulsivity), and (5) assess cost of different recruitment approaches.
Women in developing countries are often at risk of micronutrient deficiencies due to inadequate micronutrient intake. Since various micronutrient deficiencies co-exist, multiple micronutrient supplements are recommended to combat their deficiencies. The purpose of this study is to assess the effects of multiple micronutrient supplements among women of reproductive age in reducing anemia compared with iron-folic acid as currently practiced in Ethiopia. The current study is a community-based individual randomized placebo-controlled trial. The trial is double blinded with three parallel groups. This trial will be conducted in three randomly selected kebeles (villages) in the Kebribeyah district in the Somali regional state. The sample size determined for this study is 305. There will be two intervention arms and one control arm in this trial. A third of participants will be in each arms. The intervention arms will will be supplemented with United Nations International Multiple Micronutrient Antenatal Preparation-Multiple Micronutrient Supplements (UNIMMAP-MMS) or iron-folic acid (IFA) and the control arm with placebos twice a week. The investigators will follow the study participants for 17 weeks. The primary outcome is a change in mean hemoglobin concentrations and reduction in anemia prevalence. Stratified randomization will be used to assign the participants randomly to the study arms. In the current trial, the outcome assessors and study subjects will both be blinded. The supplements being administered to participants, as well as who is in the intervention group and who is in the control group, will be masked from the assessors. The trial participants will be blinded to the kind of supplements being administered to them or the group to which they were assigned. The allocation sequence of participants will be concealed from the researcher who will assign the participants to the study arms. When the eligible woman meets the screening criteria and gives informed consent, she will be assigned an envelope that contains an allocation sequence. As outcome measures, the investigators will assess the reduction in overall anemia and iron deficiency anemia attributable to the supplementation. In addition, a complete blood count (CBC) will be tested for all study participants.
Disclosed herein are methods of producing glyco-modified viral antigens that provide a shift of the glycosylation profile of recombinant produced viral antigens (e.g. glycoproteins) towards the naturally occurring viral antigens (e.g. glycoproteins). Disclosed are methods of producing a modified viral antigen comprising expressing a viral antigen in a recombinant mammalian cell line having one or more of the endogenous genes Mgat2, Mgat4A, Mgat4B, Mgat5, St3Gal3, St3Gal4, B4galtl, B4galt2, B4galt3, B4galt4, B4galt5, B3gnt2, St3Gal6, SPPL3, and/or FUT8 inactivated and/or downregulated; and optionally a gene ST6Gall inserted. Disclosed are glyco-modified viral antigens produced by the method of using a recombinant mammalian cell line. Disclosed are methods of treating a subject in need thereof comprising administering a composition comprising a therapeutically effective amount of one or more of the glyco-modified viral antigens. Disclosed are methods of screening for an antibody specific to one or more of the disclosed glyco-modified viral antigens.
The first part of the present invention concerns the extraction, purification, fractionation and identification of glycosaminoglycans composing Scyliorhinus cuniculu cartilage, recovered from the co-products. It is a cartilaginous fish belonging to the family Scryliohinidae, mainly found in the Atlantic Ocean and the Mediterranean Sea. This part comes under the theme of co-products valorization. Such biomass is commonly generated by fish processing which are systematically rejected to the environment and not used. Two glycosaminoglycans have been isolated and identified: pure chondroitin sulfate (CS) and dermatan sulfate (OS), as well as CS/OS copolymer. The purity of these molecules was studied according to many methods, especially for chondroitin sulfate, which has a monograph in the European pharmacopoeia, and has been the subject of physico-chemical analyzes in order to study its compatibility to the required standards. This allows these molecules to be used in nutraceuticals and cosmetics as well as in pharmaceuticals. Indeed. CS has essentially lubrificative and anti-inflammatory properties of the cartilaginous tissue, it regresses the osteoarthritic symptoms considerably when it is administered as a dietary supplement. OS has an anticoagulant activity and it has been shown to be effective and safer than Heparin, which has been used for decades and has many side effects. CS / OS chains are however involved in cytokinesis, cell proliferation, differentiation, migration, morphogenesis and organogenesis. The second component of the invention was to judge the purity of these molecules.
To provide methods for modifying melanin distribution and compositions for modifying melanin distribution.SOLUTION: A method and a composition for modifying melanin distribution are disclosed. A method and a composition for decreasing melanin distribution are also disclosed. A representative compound comprises 4-ethoxybenzaldehyde and one or more additional activating agents, and a pharmaceutically acceptable carrier or excipient. The carrier or excipient may be blended for topical administration. The composition may also be formulated for transdermal administration. The composition can be used for preventing or treating pigmentation disorders, for example, but not limiting thereto, post-inflammatory pigmentation. This composition may be used for lightening skin color.SELECTED DRAWING: None
Pemphigus is a severe chronic dermatological disease which appears to be incurable. Oral glucocorticoid now forms the cornerstone of treatment. From previous uncontrolled studies it has been suggested, that the use of high dose intravenous glucocorticoid pulse therapy may lead to complete remission without further therapy. Prospective placebo-controlled studies of adjuvant pulse therapy for pemphigus are lacking. This prospective, multi-centre, randomised, double-blind, placebo-controlled trial assesses the efficacy and steroid-sparing effect of oral high-dose glucocorticoid pulse therapy as adjuvant added to the standard combination therapy of prednisone and azathioprine in the treatment of pemphigus vulgaris, in terms of complete remission rate (primary endpoint), initial control, disease control, and adverse events. In the experimental arm glucocorticoid pulse therapy is given, comprising monthly pulses with 300mg oral dexamethasone on three consecutive days. In addition the patients receive daily prednisone and azathioprine treatment, the latter dose adjusted to the thiopurine-methyltransferase level. In the control arm the glucocorticoid pulse therapy is replaced double blindly by monthly oral placebo capsules on three consecutive days. in addition the patients receive the same daily combination schedule with prednisone and azathioprine as in the experimental arm. This study design requires 30 patients in each arm, with one year follow-up. Only new patients with pemphigus vulgaris and/or pemphigus oris are included.
BACKGROUND: TANK-binding kinase 1 (TBK1) is a pivotal mediator of innate immunity, activated by receptors such as mitochondrial antiviral signaling protein (MAVS), stimulator of interferon genes (STING), and TIR-domain-containing adaptor inducing interferon-β (TRIF). It modulates immune responses by exerting influence on the type I interferons (IFN-Is) signaling and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways, Over the past few years, TBK1 multifaceted role in both immune and inflammatory responses is increasingly recognized.
METHODS AND RESULTS: This review aims to scrutinize how TBK1 operates within the NF-κB pathway and the interferon regulatory transcription factor 3 (IRF3)-dependent IFN-I pathways, highlighting the kinases and other molecules involved in these processes. This analysis reveals the distinctive characteristics of TBK1's involvement in these pathways. Furthermore, it has been observed that the role of TBK1 in exerting anti-inflammatory or pro-inflammatory effects is contingent upon varying pathological conditions, indicating a multifaceted role in immune regulation.
DISCUSSION: TBK1's evolving role in various diseases and the potential of TBK1 inhibitors as therapeutic agents are explored. Targeting TBK1 may provide new strategies for treating inflammatory disorders and autoimmune diseases associated with IFN-Is, warranting further investigation.
BACKGROUND: Emergence agitation is a transient confusional state of a child associated with consciousness from general anaesthesia, commonly occurs in the postoperative setting which delays their recovery and exposes them to traumas. The main objective of the current study was to investigate the magnitude of emergence agitation, its interventions and associated factors among paediatric surgical patients at Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
METHODS: Hospital based cross-sectional study with prospective follow-up framework was conducted on a paediatric surgical patients aged 2-14 years who underwent surgery under general anaesthesia between June 1 - October 30 2022. Stratified sampling method followed by simple random sampling technique was employed to reach study participants. Magnitude of emergence agitation and its interventions done at post-anaesthetic care units were recorded. Data analysis was carried out using a descriptive statistics method and the results were summarized using tables and diagrams. Bivariate analysis was done to identify causal relationship and multivariable analysis to assess the confounding effects of factors associated with emergence agitation. A p-value of less than 0.05 was considered statistically significant factor.
RESULTS: A total of 150 participants were included in the current study, where 107 (71.3%) were male and 97 (64.7%) were preschool aged. About 81 (54%) of care givers were female and majority of them have completed primary school. The mean (standard deviation) age of the participants was 6.4 (3.57) years. Around 42.7% of them developed emergence agitation with an average duration of 8.39 ± 4.45 minutes. Factors such as propofol administration at the end of procedure (OR of 0.104 with 95% CI [0.035, 0305]), Ear, nose, throat surgery and oral maxillofacial surgery (OR of 2.341 with 95% CI [1.051, 5.211]) and arrival of patient to recovery awake (OR of 0.456 95% CI [0.209, 0.994]) showed statistically significant association with emergence agitation.
CONCLUSION: Almost half of the study participants experienced emergence agitation which is high magnitude. Ear, nose, throat surgery and oral maxillofacial surgeries were predictive factors of emergence agitation while propofol administration at the end of procedure and arrival of patient to recovery awake significantly decreased risk of emergence agitation. Therefore, anaesthesia personnel should have essential skills and knowledge to effectively care for children perioperatively including to minimize and treat emergence agitation.
A mixture of penicillin or a non-toxic salt thereof and novobiocin or dihydronovobiocin, or a non-toxic salt thereof, is used as a feed supplement in promoting the growth of animals and poultry either alone or in combination with other antibiotics. The penicillin may be any penicillin, e.g. penicillin G, O or V, and the salts may be alkali metal salts such as sodium and potassium salts or amine salts such as the procaine and N,N1-dibenzylethylenediamine salts.  The salts of novobiocin and dihydronovobiocin are the alkali metal, e.g. sodium and potassium, the alkaline earth metal such as calcium and magnesium, and amine salts.  Specifications 815,517 and 815,518 are referred to.ALSO:An antibiotic composition comprises penicillin, or a non-tonic salt thereof, and novobiocin or dihydronovobiocin, or a non-tonic salt thereof.  The penicillin may be any penicillin, e.g. penicillin G, O or V; and the salts may be alkali metal salts such as sodium and potassium salts or amine salts such as the procaine and N,N1-dibenzylethylene diamine salts.  The salts of novobiocin and dihydronovobiocin are the alkali metal, e.g. sodium and potassium salts, the alkaline earth metal such as calcium and magnesium salts and amine salts.  Proportions range from 1 to 20 to 20 to 1 equal quantities being preferred.  The compositions may be in the form of pharmaceutical preparations for internal or external use and for the treatment of humans and animals.  Such preparations may be tablets, powders, granules, capsules, suspensions for oral or parenteral use, ointments, lotions, sprays, nosedrops, troches and suppositories. Suspensions may be in water or edible oil, e.g. one containing aluminium monostearate.  Aqueous suspensions may contain a hydrophillic colloid such as sodium carboxymethylcellulose, methyl cellulose, polyvinyl pyrrolidone, gelatin and tragacanth.  Ointments may be prepared with a petrolatum type base.  Optional ingredients are (a) sulpha drugs such as sulphadiazine, sulphamethazine and sulphamerazine especially together; (b) other antibiotics such as chloramphenicol, erythramycin, tetracycline, oxytetracycline and chlortetracycline; (c) vitamins such as thiamine, riboflavin, ascorbic acid, niacinamide, pyridoxine, pantothenic acid or a salt thereof, Vitamin B12 and folic acid; (d) corticoids, e.g. cortisone, hydrocortisone and the 21 esters thereof; prednisone and prednisolone and the 21 esters thereof; 2-methyl hydrocortisone and the 21 esters thereof; such esters being the acetate, cyclopentylpropionate, hemisuccinate, hemiglutarate and hemi beta, beta-dimethyl glutarate and the water-soluble salts of the last three esters.  Specifications 815,517 and 815,518 are referred to.
New proteins (I) comprise the feline CD4 protein (Ia), with the amino acid sequence shown in the fig., and active fragments of (Ia) contg. the binding site for a feline immunodeficiency virus (FIV) capable of binding to (Ia). Also claimed are: (1) DNA sequences coding for (I); (2) recombinant vectors capable of transforming host cells and contg. a DNA sequence coding for (I) under the control of a promoter recognised by the polymerase of the host cell under conditions such that the DNA sequence is expressed in the host cell; (3) host cells transformed with the vectors of (2); (4) a method for selection of FIVs interacting with feline CD4, comprising contacting an FIV-infected cell culture supernatant with the host cells of (3) and selecting those viruses capable of penetrating into the host cells by interacting with their CD4; and (5) veterinary compsns. contg. (Ia) or a water-soluble fragment of (Ia). USE - The method may be used to study the CD4 affinity of different FIV isolates and to gain information about the acquisition of CD4 affinity by lentiviruses in general, including HIV.
Blood draw, processing of PRP, white blood cell poor, high platelet multiple \>/= 4, e.g. (Emcyte II Pure PRP) Endovaginal ultrasound guided intra-ovarian placement into ovarian parenchyma, preferably both if accessible.
XENICAL (orlistat) is a gastrointestinal lipase inhibitor for obesity management that acts by inhibiting the absorption of dietary fats.

Orlistat is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]-dodecyl ester. Its empirical formula is C 29H 53NO 5, and its molecular weight is 495.7. It is a single diastereomeric molecule that contains four chiral centers, with a negative optical rotation in ethanol at 529 nm. The structure is:

Orlistat is a white to off-white crystalline powder. Orlistat is practically insoluble in water, freely soluble in chloroform, and very soluble in methanol and ethanol. Orlistat has no p Ka within the physiological pH range.

XENICAL is available for oral administration as a turquoise hard-gelatin capsule. The capsule is imprinted with black. Each capsule contains a pellet formulation consisting of 120 mg of the active ingredient, orlistat, as well as the inactive ingredients microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone, and talc. The capsule shell contains gelatin, titanium dioxide, and FD&C Blue No. 2 with black printing ink containing pharmaceutical grade shellac, propylene glycol, strong ammonium solution, potassium hydroxide and black iron oxide.
In cohort-B, the gene alteration that MTB combines with clinical practice and literature reports that can match targeted therapy is considered to be potential actionable targets. Cohort-B also includes different observation subgroups and clinical trials may conduct in each subgroup. For example, substudy-B1(TP53 as driver gene), substudy-B2(RAS as driver gene), substudy-B3(MAP2K1 as driver gene), substudy-B4(PTEN Loss as driver gene), substudy-B5(11q13 co-amplification as driver genes), Substudy-B6(concomitant actionable alterations), substudy-B7(other driver genes). MTB-guided therapy was defined as having a clinical benefit if the PFS ratio between the longest PFS on MTB-guided therapy and the PFS on the last therapy before MTB-guided therapy was ≥1.3 (i.e., using patients as their own controls) for each substudy. To meet the primary objective, at least 35% of participants had to achieve a PF2S/PFS1 ≥ 1.3 in a sample population of 25 evaluable patients.
Households recruited into intervention arm two will receive livestock feeds similar to intervention arm 1 and will be enrolled in a nutritional education and counselling program through Infant and Young Child Nutrition (IYCF) feeding program and household food utilization. The IYCF program through the Baby Friendly Community Initiative (BFCI) will include the promotion of exclusive breastfeeding in the first six months, continued breastfeeding up to the age of two years, adequate complementary feeding, hygiene promotion and the uptake of child health services including immunization, treatment of illness, moderate and severe acute malnutrition and micro-nutrient supplementation.
PURPOSE:To obtain an oily or fatty ointment for treating psoriasis, containing 1alpha,24(R)-dihydroxycholecarciferol as an active ingredient and having improved efficacy, safety and stability. CONSTITUTION:A oily or fatty ointment for treating psoriasis obtained by dissolving 1alpha,24(R)-dihydroxycholecarciferol in a hydrophobic or anhydrous solvent and blending the resultant solution with an oily or fatty base. The solvent is one or a blend of two or more selected from the group consisting of fatty acid esters, e.g. diisopropyl adipate, higher alcohols, e.g. octyldodecanol, and propylene carbonate and used in an amount of 0.01-25.0wt.% based on the ointment. The oily or fatty base is one or a blend of two or more selected from the group of white petrolatum, yellow petrolatum, liquid paraffin and polyethylene gel of the liquid paraffin. The 1alpha,24(R)-dihydroxycholecarciferol is blended in an amount of 1ng-2mg based on 1g ointment.
No dosage adjustment is recommended for elderly patients [see also Boxed Warning, Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].   


Of the 13,543 patients treated with oral aripiprazole in clinical trials, 1073 (8%) were ≥65 years old and 799 (6%) were ≥75 years old. Placebo-controlled studies of oral aripiprazole in schizophrenia, or other indications did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Of the 749 patients treated with aripiprazole injection in clinical trials, 99 (13%) were ≥65 years old and 78 (10%) were ≥75 years old. Placebo-controlled studies of aripiprazole injection in patients with agitation associated with schizophrenia or bipolar mania did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. 

Aripiprazole is not approved for the treatment of patients with psychosis associated with Alzheimer’s disease [see also Boxed Warnings and  Warning and Precautions ( 5.1)].